

Martin Kleinschmidt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3800304/publications.pdf>

Version: 2024-02-01

9
papers

465
citations

1162889
8
h-index

1474057
9
g-index

9
all docs

9
docs citations

9
times ranked

691
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides. <i>Biochemistry</i> , 2009, 48, 7072-7078.	1.2	171
2	Pyroglutamate-3 Amyloid- β^2 Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models. <i>American Journal of Pathology</i> , 2013, 183, 369-381.	1.9	102
3	Passive Immunization against Pyroglutamate-3 Amyloid- β^2 Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. <i>Neurodegenerative Diseases</i> , 2012, 10, 265-270.	0.8	63
4	An anti-pyroglutamate-3 A β^2 vaccine reduces plaques and improves cognition in APP ^{swe} /PS1 ^{E9} mice. <i>Neurobiology of Aging</i> , 2015, 36, 3187-3199.	1.5	45
5	Effector function of anti-pyroglutamate-3 A β^2 antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 12.	3.0	26
6	Structural and functional analyses of pyroglutamate-amyloid- β^2 -specific antibodies as a basis for Alzheimer immunotherapy. <i>Journal of Biological Chemistry</i> , 2017, 292, 12713-12724.	1.6	24
7	Development of the clinical candidate PBD-C06, a humanized pGlu3-A β^2 -specific antibody against Alzheimer's disease with reduced complement activation. <i>Scientific Reports</i> , 2020, 10, 3294.	1.6	17
8	Targeting isoaspartate-modified A β^2 rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 149.	3.0	10
9	Structure and Dynamics of Meprin β^2 in Complex with a Hydroxamate-Based Inhibitor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5651.	1.8	7